- Previous Close
0.0300 - Open
0.0300 - Bid 0.0250 x --
- Ask 0.0300 x --
- Day's Range
0.0300 - 0.0300 - 52 Week Range
0.0200 - 0.0600 - Volume
1,661 - Avg. Volume
54,051 - Market Cap (intraday)
5.074M - Beta (5Y Monthly) 0.15
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Dec 23, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jul 21, 2005
- 1y Target Est
--
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company's lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for the potential cancer targets include pancreatic, colon, leukemia, ovarian, and breast cancer. It is also involved in the development of Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. The company is headquartered in Edmonton, Canada.
www.questpharmatech.comRecent News: QPT.V
View MorePerformance Overview: QPT.V
Trailing total returns as of 1/3/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: QPT.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: QPT.V
View MoreValuation Measures
Market Cap
5.07M
Enterprise Value
5.89M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.22
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-1.97%
Return on Equity (ttm)
-11.79%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-2.88M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
321.43k
Total Debt/Equity (mrq)
4.35%
Levered Free Cash Flow (ttm)
111.61k